Immune Design, Theravectys infectious, cancer news
Theravectys filed a suit against Immune Design in the Delaware Court of Chancery. The suit alleges that Immune Design induced Theravectys’ exclusive manufacturer, Henogen S.A., to breach exclusivity obligations by manufacturing and supplying cGMP clinical batches of lentiviral vectors for Immune Design. Groupe Novasep S.A.S. (Pompey, France) acquired Henogen in July.
Theravectys raises claims of tortious interference with contractual relations, misappropriation of trade secrets, unfair competition and unjust enrichment. Theravectys is seeking monetary damages, plus injunctive relief preventing Immune Design from using lentiviral vector vaccines produced by Henogen. Immune Design said it is not currently using Henogen to manufacture clinical lentiviral vectors for clinical trials. Immune Design also said it had developed and transferred its own manufacturing process to Henogen and had no knowledge of Theravectys’ processes. ...